Brighter’s pioneering diabetes management solution Actiste® receives market approval in the Kingdom of Saudi Arabia
Brighter AB (publ) is proud to announce that its pioneering solution for improved diabetes management – the Actiste® device and its associated digital platform – has received market approval from the Saudi Food and Drug Authority (SFDA). Some additional regulatory approvals for consumables included within the Actiste® Diabetes Management as a Service (“Actiste Service”) offering, as well as the cellular transmission approval from the Saudi Telecoms Authority, are still outstanding. However, they remain on track and are anticipated to be granted by Q1 2021. On receipt of all required